about
Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsTowards a rational design of solid drug nanoparticles with optimised pharmacological properties.Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz.CLEFT PALATE IN HIV-EXPOSED NEWBORNS OF MOTHERS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY.Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial)Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals.Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation.Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.A systematic review of the psychiatric side-effects of efavirenz.Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz.Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications.Role of Cytochrome P450 2B6 Pharmacogenomics in Determining Efavirenz-Mediated Central Nervous System Toxicity, Treatment Outcomes, and Dosage Adjustments in Patients with Human Immunodeficiency Virus Infection.Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.Effect of Valerian in Preventing Neuropsychiatric Adverse Effects of Efavirenz in HIV-Positive Patients: A Pilot Randomized, Placebo-Controlled Clinical Trial.Efavirenz does not meaningfully affect the single dose pharmacokinetics of 1200 mg raltegravir.In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells.Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy.Allosteric activation of cytochrome P450 3A4 by efavirenz facilitates midazolam binding.Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015.A validated liquid chromatography tandem mass spectrometry method for the analysis of efavirenz in 0.2 mg hair samples from HIV-infected patients.Semisimultaneous Midazolam Administration to Evaluate the Time Course of CYP3A Activation by a Single Oral Dose of Efavirenz.Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.Access to benzo-fused nine-membered heterocyclic alkenes with a trifluoromethyl carbinol moiety via a double decarboxylative formal ring-expansion process under palladium catalysis.
P2860
Q28081266-0291C38D-E71F-4841-9EAA-9E7A927FD7EFQ30372133-AE38BB7D-E301-4063-B01F-8350A253A7DDQ34503553-CEB64668-7D99-4985-8F32-13F1C341E831Q35038144-C92222B3-5E6E-4282-8FE8-4E2CFB4EC8DDQ35114865-DDC68A55-05AF-4517-96AF-05119F1760EBQ35547048-5426C44B-3EA1-4FA6-9DA5-7F53A591BBA5Q35692270-9850DA71-8931-4C76-B411-5460BC1B1D25Q36993483-6A3DBB15-B133-4B9D-8716-83415373B7EDQ37538717-BC4F922A-8FBB-4A90-AC02-BFC714EDB0FBQ37826300-C144440B-9A1D-41ED-A1F4-90B381A83A46Q37864141-69505237-C985-43BC-9986-1ACFED6AD230Q38083294-37E08CD8-16EC-4213-A5A1-5734ED678D76Q38175870-1DFC28E6-51E7-43C6-9A5B-DE4ED761EE24Q38194963-6EB4B779-6882-447C-A929-27732BA0C3F9Q38990321-2B2E47F4-CE64-43B0-B9D9-90CEE8F429F4Q39418438-9FF969BB-7817-40CD-B02C-0D7CDFD04E44Q40223622-A449AB4A-6182-4422-A35E-5027E84ED8CFQ40516335-405D1A0A-493E-4979-BF13-81C37D6143E8Q41668874-CC1507ED-EC2C-4C27-B233-50A55BAC6C6FQ43011656-C280E56B-35FD-4F40-9D9D-D9A403029A43Q47117336-137A1C0D-C0AA-4990-AF5A-0B6AB268C350Q47345997-1A027267-793A-4185-863B-A99C86562978Q48500206-9765EAE6-5908-4A8A-8ADC-64EFB983FE37Q49629769-38245D51-F894-4348-B4B7-F8FF77AB2202Q50051675-A823E6C2-47DD-4986-9186-F76090EDF02EQ50052945-0423EFBC-AC03-4762-A6BC-532115BBD954Q50894716-613A8A09-0D9D-4BED-8B1F-DB57C824979AQ51051365-A66CDF64-519F-4CCF-9848-376895B332EEQ55408709-93762DF6-8441-4E2B-AB09-B6B5003FD030
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Efavirenz: a review.
@en
type
label
Efavirenz: a review.
@en
prefLabel
Efavirenz: a review.
@en
P2093
P2860
P356
P1476
Efavirenz: a review.
@en
P2093
Ferdinand W N M Wit
Jacqueline van Tongeren
Joep M A Lange
Saskia M E Vrouenraets
P2860
P304
P356
10.1517/14656566.8.6.851
P407
P577
2007-04-01T00:00:00Z